ArticleTranslational andrology and urology2024
Development of a machine learning-based predictive model for transitional cell carcinoma of the renal pelvis in White Americans: a SEER-based study.
Article in Translational andrology and urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transitional cell carcinoma (TCC) of the renal pelvis is a rare cancer within the urinary system. However, the prognosis is not entirely satisfactory. This study aims to develop a clinical model for predicting cancer-specific survival (CSS) at 1-, 3-, and 5-year for White Americans with renal pelvic TCC. Methods: Data of all White American patients diagnosed with TCC of the renal pelvis from 2010 to 2015 were extracted and analyzed from the Surveillance, Epidemiology, and End Results (SEER) database in this retrospective study. Subsequently, after excluding the metastatic group, a subgroup analysis was performed on the data of 1,715 White Americans with non-metastatic renal pelvic TCC. Patients included in this study were randomly divided into the training and validation sets in a ratio of 7:3. In addition, the features in the training set were extracted by the Boruta algorithm. The importance of these features was visualized using the eXtreme Gradient Boosting (XGBoost)-based SHapley Additive exPlanation (SHAP) tool. To improve predictive accuracy, a nomogram model with these identified independent prognostic variables was developed. Results: A total of 1,887 White American patients with renal pelvic TCC were included in this study. In the training set, the area under the curve (AUC) for CSS nomograms at 1-, 3-, and 5-year were 0.813 [95% confidence interval (CI): 0.774-0.852], 0.738 (95% CI: 0.702-0.774), and 0.733 (95% CI: 0.698-0.768), respectively. Correspondingly, the AUCs for CSS nomograms at the above time points were 0.781 (95% CI: 0.732-0.830), 0.785 (95% CI: 0.741-0.829), and 0.775 (95% CI: 0.729-0.820) in the validation set, respectively. The subgroup analysis results revealed that the AUCs for CSS nomograms at 1-, 3-, and 5-year were 0.788, 0.725, and 0.726 in the training set, respectively, while the AUCs for CSS nomograms at 1-, 3-, and 5-year were 0.831, 0.786, and 0.754 in the training set, respectively. Conclusions: In this study, a nomogram that predicts CSS in White American patients diagnosed with renal pelvic TCC was efficiently constructed. The application of the nomogram may enhance patient care and assist clinicians in choosing the optimal treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.